cis-4-Methyl-cyclohexylcarbinylamin | 35388-77-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: cis-4-Methyl-cyclohexylcarbinylamin
• CAS: 35388-77-3
• 化学式: C₈H₁₇N
• 分子量: 127.23
• InChiKey: ZMKGMRDHYTYLDH-OCAPTIKFSA-N

文献信息

• FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS
  申请人：Hangeland Jon J.

  公开号：US20090036438A1

  公开（公告）日：2009-02-05

  The present invention provides a method for treating a thrombotic or an inflammatory disorder administering to a patient in need thereof a therapeutically effective amount of at least one compound of Formula (I) or Formula (V): or a stereoisomer or pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L, Z, R 3 , R 4 , R 6 , R 11 , X 1 , X 2 , and X 3 are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also provides compounds within the scope of Formula I and relates to pharmaceutical compositions comprising these compounds.

  本发明提供了一种治疗血栓性或炎症性疾病的方法，该方法向需要治疗的患者施用至少一种公式（I）或公式（V）中的化合物的治疗有效量：或其立体异构体或药学上可接受的盐或溶剂形式，其中变量A、L、Z、R3、R4、R6、R11、X1、X2和X3如本文所定义。公式（I）的化合物可用作凝血级联和/或接触激活系统的丝氨酸蛋白酶酶的选择性抑制剂；例如凝血酶、因子Xa、因子XIa、因子IXa、因子VIIa和/或血浆激肽。特别是，涉及到选择性因子XIa抑制剂的化合物。本发明还提供了公式I范围内的化合物，并涉及包含这些化合物的制药组合物。
• Diaminopropionic acid derivatives
  申请人：Fotouhi Nader

  公开号：US20070155671A1

  公开（公告）日：2007-07-05

  A compound of formula 1a which is useful for treating reperfusion injury, and salts, prodrugs, and related compounds.

  化合物1a的公式，对于治疗再灌注损伤是有用的，包括盐类、前药和相关化合物。
• [EN] MALT1 MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DE MALT1 ET LEURS UTILISATIONS
  申请人：RHEOS MEDICINES INC

  公开号：WO2022081967A1

  公开（公告）日：2022-04-21

  Provided herein are compounds, compositions, and methods useful for modulating MALT1 and for treating related diseases, disorders, and conditions.

  本文提供了用于调节MALT1并治疗相关疾病、障碍和病况的化合物、组合物和方法。
• US7491741B2
  申请人：——

  公开号：US7491741B2

  公开（公告）日：2009-02-17
• US8101778B2
  申请人：——

  公开号：US8101778B2

  公开（公告）日：2012-01-24